Cookies

Like most websites The Analytical Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Techniques & Tools Metabolomics & Lipidomics, Business, Technology

Joining Forces: Rise of the Omics

Tell us about your project…

Mark Viant: We have two metabolomics research centers here at the University of Birmingham – the Phenome Centre Birmingham, which is a £8 million research center opened by UK Government Chief Scientific Adviser Professor Sir Mark Walport in May 2016, and the Birmingham Metabolomics Training Centre. Thermo Fisher Scientific is technology partner with both of those research centers and with the University’s proteomics program. Helen Cooper, a professor of mass spectrometry here at Birmingham, leads the proteomics part of the relationship, while Rick (Warwick) Dunn and I lead the metabolomics side. Rick and I have a joint lab with about 25 PhDs, postdocs and technicians, and we direct both the training center and the Phenome Centre.

Phenome Centre-Birmingham (PCB) conducts metabolic phenotyping (metabolomics) studies across the breadth of human health research. We apply both non-targeted and targeted metabolomic approaches to study human diseases and aging in large-scale studies to translate into stratified medicine, ultimately benefiting both UK and global populations. Specifically we use these approaches to measure the “metabolome” of patients – the set of naturally occurring metabolites in cells, tissue or biofluids such as plasma or urine. The big data that is generated is then analyzed using bioinformatics and biostatistical tools to understand molecular mechanisms associated with disease onset and progression, and to identify clinically relevant metabolic markers (biomarkers) that could be used to stratify the human population in terms of disease risk and choice of drug treatment. Current projects include metabolomics studies of reproductive medicine, blood cancers, trauma and organ transplantation.

Thermo Fisher works with us on a number of levels. They currently fund multiple Cooperative Awards in Science & Technology (CASE) PhDs in metabolomics here in Birmingham that provide a bedrock for our collaboration. As well as input from Thermo Fisher on the scientific direction of these projects, the PhD students visit the Thermo Fisher analytical laboratories, spending time working with their scientists – that’s a pretty deep interaction and a great experience for the students, who are more used to an academic research environment. We also beta-test some of their instrumentation and software – and that means we get early access!

Read the full article now

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Authors

Mark Viant

Professor of Metabolomics, University of Birmingham, UK.


Iain Mylchreest

Vice President, R&D, analytical instruments, Thermo Fisher Scientific.

Newsletter

Send me the latest from The Analytical Scientist.

Sign up now

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine

Register